Tier 4 — mechanistic

What is really known about the effects of nicotinamide riboside supplementation in humans

Damgaard MV, Treebak JT
Science advances 2023 9; 29; eadi4862

Bibliography

PubMed
PMID 37478182
PubMed Central
PMC10361580
DOI
10.1126/sciadv.adi4862
Funding
Funding details are not specified in the accessible publication information.
Competing interests
A complete competing-interest declaration is not specified in the accessible publication information.

Study snapshot

DesignNarrative evidence review
ModelPublished human research literature
Sample25 human NR supplementation publications reviewed
InterventionReview of human NR supplementation studies
DurationLiterature available at the 2023 review
EndpointsEvidence synthesis and translational limitations

What the study showed, in plain terms

The review distinguished reliable NAD+ biomarker increases from the limited and inconsistent evidence for clinically important effects.

Key findings

The review distinguished reliable NAD+ biomarker increases from the limited and inconsistent evidence for clinically important effects.

What this study can and cannot tell us

Narrative critical review, not a pooled estimate. It predates newer trials and must be read with the later primary studies.

Related papers in the corpus

Tier 4
Emerging strategies, applications and challenges of targeting NAD + in the clinic
Zhang J et al. · Nature aging · 2025
Tier 4
Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions
Freeberg KA et al. · The journals of gerontology. Series A, Biological sciences and medical sciences · 2023
Tier 4
NAD + Precursors in Human Health and Disease: Current Status and Future Prospects
Yaku K et al. · Antioxidants & redox signaling · 2023
Tier 4
Balancing NAD + deficits with nicotinamide riboside: therapeutic possibilities and limitations
Cercillieux A et al. · Cellular and molecular life sciences : CMLS · 2022
Tier 1
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis
Zhong O et al. · Nutrition & metabolism · 2022
Tier 4
Preclinical and clinical evidence of NAD + precursors in health, disease, and ageing
Reiten OK et al. · Mechanisms of ageing and development · 2021

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology